Sage Therapeutics Inc. buy klostergang
Start price
24.11.18
/
50%
€102.23
Target price
04.11.21
€95.00
Performance (%)
-55.47%
End price
17.06.21
€45.52
Summary
This prediction ended on 17.06.21 with a price of €45.52. Massive losses of -55.47% were the result for the BUY prediction by klostergang. klostergang has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Sage Therapeutics Inc. | - | - | - | - |
| iShares Core DAX® | 0.060% | 1.215% | 18.128% | 70.406% |
| iShares Nasdaq 100 | -3.065% | -0.519% | 2.080% | 103.787% |
| iShares Nikkei 225® | -2.094% | -3.066% | 11.655% | 45.417% |
| iShares S&P 500 | -1.657% | -0.069% | 1.103% | 64.908% |
Comments by klostergang for this prediction
In the thread Sage Therapeutics Inc. diskutieren
klostergang stimmt dem Sentiment von 'Buy' zu
FDA advisors voted 18-0 that Zulresso (brexanolone) is effective for treatment of postpartum depression despite some reservations about the safety of home infusion.
An FDA decision is expected by December 19.
Update
: The vote was 17-1 that the drug's benefits outweigh the risks.
Kursziel geändert auf 95,0
Stopped prediction by klostergang for Sage Therapeutics Inc.
Sage Therapeutics Inc.
Start price
Target price
Perf. (%)
€76.06
09.06.15
09.06.15
€75.00
09.06.15
09.06.15
0.00%
09.06.15
09.06.15
